<DOC>
	<DOCNO>NCT00001042</DOCNO>
	<brief_summary>To determine healthy HIV-negative volunteer safety immunogenicity rgp120/HIV-1SF2 ( BIOCINE ) formulate seven adjuvant . PER AMENDMENT 3/6/96 : Purpose extension study - To determine ability immunization rgp 120/SF-2 induce HIV-1 envelope-specific delayed-type hypersensitivity ( DTH ) response volunteer receive rsgp 120/MN skin testing . One approach improve immunogenicity HIV-1 subunit protein vaccine combine immunogen adjuvant . Adjuvants may augment vaccine immunogenicity several mechanism , result induce favorable antibody response high titer , appear early course immunization persist time .</brief_summary>
	<brief_title>A Phase I , Randomized , Double-Blind , Placebo-Controlled , Clinical Trial Compare Safety Immunogenicity Recombinant Envelope Protein rgp120/HIV-1SF2 ( BIOCINE ) Combined With Seven Adjuvants Healthy HIV-1 Uninfected Individuals</brief_title>
	<detailed_description>One approach improve immunogenicity HIV-1 subunit protein vaccine combine immunogen adjuvant . Adjuvants may augment vaccine immunogenicity several mechanism , result induce favorable antibody response high titer , appear early course immunization persist time . Volunteers randomize receive 50 mcg rgp120/HIV-1SF2 combination one seven different adjuvant : aluminum hydroxide ( alum ) , monophosphoryl lipid A , liposome-encapsulated monophosphoryl lipid A , MF59 , MTP-PE/MF59 , Syntex adjuvant formulation ( SAF/2 ) , SAF/2 plus threonyl muramyl dipeptide ( threonyl MDP ) . An additional placebo control arm volunteer receive alum . Doses administered 0 , 2 , 6 month . Volunteers follow 1 year last immunization . Per 8/5/94 amendment , eligible volunteer except receive monophosphoryl lipid A first three immunization may receive fourth dose month 15 . PER AMENDMENT 3/6/96 : Extension Study- Protocol 015 modify add special DTH study . At end study , day 784 , intradermal injection MN rsgp 120 administered consent volunteer receive 4 immunization part protocol 015 . Follow extend 56 day administration intradermal injection .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<mesh_term>Acetylmuramyl-Alanyl-Isoglutamine</mesh_term>
	<criteria>Inclusion Criteria Subjects must : HIV negativity ELISA . Normal history physical exam . CD4 count &gt; = 400 cells/mm3 . Lower risk sexual behavior . Normal urine dipstick esterase nitrite . PER AMENDMENT 3/6/96 : Extension study Consenting Protocol 015 volunteer receive four immunization . Exclusion Criteria Coexisting Condition : Subjects follow symptoms condition exclude : Hepatitis B surface antigen . Active syphilis . NOTE : Subjects serology document false positive due remote ( &gt; 6 month ) treat infection eligible . Active tuberculosis . NOTE : Subjects positive PPD normal chest xray show evidence TB require isoniazid therapy eligible . Medical psychiatric condition occupational responsibility would preclude compliance . Subjects follow prior condition exclude : History immunodeficiency , chronic illness , autoimmune disease . History anaphylaxis serious adverse reaction vaccine . PER AMENDMENT 3/6/96 : Extension study History eczema allergictype reaction vaccine Protocol 015 . Prior Medication : Excluded : Live attenuate vaccine within 60 day prior study entry . ( NOTE : Medically indicate subunit kill vaccine , influenza pneumococcal , allow give least 2 week prior HIV immunization . ) Experimental agent within 30 day prior study entry . Prior HIV vaccine . PER AMENDMENT 3/6/96 : Extension study Use systemic steroid past month . Prior Treatment : Excluded : Blood product immunoglobulin within 6 month prior study entry . Higher risk behavior HIV infection ( determined screen questionnaire ) , include history injection drug use within last 12 month high intermediate risk sexual behavior .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Adjuvants , Immunologic</keyword>
	<keyword>HIV Envelope Protein gp120</keyword>
	<keyword>Acetylmuramyl-Alanyl-Isoglutamine</keyword>
	<keyword>monophosphoryl lipid A</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>